TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04551365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle changes
Description: Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Lifestyle changes
Description: Interdisciplinary rehabilitation programmes 5 days per week, for 4-6 weeks. The aim of the rehabilitation programme is to improve lifestyle through improved planning of activities of daily life, improved planning of food intake, increased physical activity, and weight loss. The focus is on physical and mental well-being and reinforcing participation in social activities. Patients are encouraged to carry on with their lifestyle changes after dismission from the program. Total duration 14 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitosan
Description: Daily intake of chitosan supplement. Daily dose: 4 capsules(1,5 g chitosan) twice at main meals; total 3 g Duration: 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily intake of placebo (Microcrystalline cellulose (MCC), and native maize food starch (FS)) Daily dose: 4 capsules(0.75 g MCC + 0.75 g FS) twice at main meals; total 3 g Duration: 12 weeks
Study: NCT02570035

Intervention type: DRUG
Intervention: Mirabegron
Description: oral
Study: NCT02503826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
Study: NCT01614106

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retention Clinic
Description: The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
Study: NCT04375098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: COVID-19 convalescent plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 convalescent plasma
Description: COVID-19 convalescent plasma
Study: NCT00427219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozarelix
Description: Ozarelix 15 mg will be administered IM on Day 0 and Day 14.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered IM on Day 0 and Day 14.
Study: NCT01041677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 10 mg capsule twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R256918
Description: 15 mg capsule twice daily
Study: NCT02536274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumbo Sensa® bandage
Description: Patients have to wear it over 21-28 days for at least 8 hours a day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynaflex® flexion orthosis
Description: Patients have to wear it over 21-28 days for at least 8 hours a day
Study: NCT03244267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Education
Description: Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Reminder App
Description: Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
Study: NCT04498039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable Neuromodulation Stimulator
Description: Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Portable Neuromodulation Stimulator
Description: Examining the effect of targeted physical therapy with and without cranial nerve non-invasive neuromodulation (CN-NINM), on the walking ability of people with MS who exhibit a dysfunctional gait. Adopting a rehabilitative strategy using neuromodulation of the cranial nerves via electrical stimulation of the tongue to enhance the plasticity of the brain.
Study: NCT03865719

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Habits for Life
Description: Healthy Habits for Life: 11-session, 6 month, one-on-one, dietician-lead weight management manualized treatment.
Study: NCT02309723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta amyloid imaging

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beta amyloid imaging
Study: NCT04389307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation (IVES)
Description: IVES sessions were performed three times in a week, for 8 weeks. Every session lasted 20 minutes. The intervention comprised a 24 session treatment program of IVES.

Intervention type: OTHER
Group type: OTHER
Intervention: Bladder Training
Description: Bladder Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Training
Description: Bladder Training
Study: NCT03927326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: Liposomal bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel 266 MG Per 20 ML Injection
Description: Liposomal bupivacaine
Study: NCT02503826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisatracurium
Study: NCT04009629

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercise
Description: Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Intensity Aerobic Exercise
Description: Participants will exercise for 15 minutes in a moderate age-predicted heart rate range. The study team will employ an exercise device such as a treadmill, cycle, or recumbent stepper to maintain control over workload.
Study: NCT00568841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-/FLT-PET
Study: NCT02760563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application (Formulation number V26-160)
Study: NCT00761956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen CR-Flex Fixed Bearing Knee
Description: NexGen CR-Flex Fixed Bearing femoral component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen CR Knee
Description: NexGen Complete Knee Solution Cruciate Retaining femoral component
Study: NCT02989090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receive Detailed ICD Information-electronic
Description: Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Receive Detailed ICD Information-paper
Description: Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
Study: NCT00954005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapy with Rituximab, Gemcitabine and Oxaliplatin
Description: Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
Study: NCT03596398

Intervention type: GENETIC
Intervention: GLA gene
Description: Genetic test will be performed when enzyme activity is found abnormal in the whole blood test or confirmation is required. 5 ml of blood sample will be obtained and polymerase chain reaction (PCR) sequencing will be executed to determine mutations in the GLA gene.
Study: NCT02106364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Peglispro
Description: Administered SQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Glargine
Description: Administered SQ
Study: NCT00949793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscope
Description: Endomicroscopic images are taken at several positions on the tumor.
Study: NCT04060771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: prophylaxis of postoperative nausea and vomiting
Study: NCT01266018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 (Arginine deiminase pegylated)
Description: ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADI-PEG 20 (Arginine deiminase pegylated)
Description: ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m\^2 (36.8 mg/m\^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
Study: NCT00656032

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: paricalcitol
Description: 1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cinacalcet
Description: 0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
Study: NCT02755701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branched-chain Amino Acid
Description: BCAA (livact) will be administered 3 times a day during 24 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in the same way
Study: NCT00966979

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon PKR
Description: Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
Study: NCT01013688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioblate® Surgical Ablation System
Description: Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioblate® Surgical Ablation System
Description: Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
Study: NCT05140681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FibReORS with apically positioned flap (apical position)
Description: Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at 2 mm subcrestal position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FibReORS with apically positioned flap (crestal position)
Description: Periodontal surgery including flap elevation. root surface scaling, bone remodeling and suture of the flap at either a crestal position
Study: NCT03003598

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope
Description: This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
Study: NCT04415645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-VVZ-149
Description: A single IV infusion of radio-labeled VVZ-149
Study: NCT02187367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EGF Vaccine
Description: 1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
Study: NCT02106195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil
Study: NCT00561717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azelastine and placebo
Description: One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine and Placebo
Description: One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetirizine and Placebo
Description: One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Placebo (spray and Tablet)
Description: One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
Study: NCT00944229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LOVAZA (Omega-3)
Description: LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules of placebo every 24 hours
Study: NCT01854736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Grazax
Description: GRAZAX

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02976168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12° head down tilt
Description: supine head down tilt
Study: NCT02656550

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine Transplant
Description: Transplant of a uterus from either a living donor or a deceased donor.,
Study: NCT02341586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lucky Iron Fish - home fortification system
Description: The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 18 mg elemental iron
Description: This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).

Intervention type: OTHER
Group type: OTHER
Intervention: Nutrition Education
Description: This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
Study: NCT01458925

Intervention type: DEVICE
Group type: OTHER
Intervention: The P1 Check-Cap capsule
Description: The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
Study: NCT01347671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 25µg/day once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 75 µg/day once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRT6005
Description: 200 µg/day once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Once daily
Study: NCT01296009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine(Zhuyun Recipe)
Description: The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
Study: NCT04060771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: prophylaxis of postoperative nausea and vomiting
Study: NCT04124328

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALINE + VoM infusion
Description: In patients assigned to the ALINE + VoM infusion group, extended ablation will be performed according to the ALINE criteria. Additionally, the vein of Marshall will be infused with ethanol.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ALINE only
Description: In patients assigned to the ALINE only, extended ablation will be performed according to the ALINE criteria.
Study: NCT00072904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Asparte
Description: Insulin asparte given 0.5 units per carb per meal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Repaglinide
Description: 0.5mg tab with meals tid
Study: NCT01897792

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin E

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Saline (for Vitamin C)
Description: 0.9% saline administered to mimic Vitamin C

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Vitamin E)
Description: Sugar pill administered to mimic Vitamin E
Study: NCT01044589

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodesign Tissue Repair Graft
Description: Biodesign Tissue Repair Graft reinforcement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overlapping Sphincter Repair
Description: Overlapping Sphincter Repair Alone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Overlapping Sphincter Repair
Description: Overlapping Sphincter Repair Alone
Study: NCT01234701

Intervention type: OTHER
Intervention: Non-invasive Magnetic Resonance Imaging (MRI)
Description: Conventional pre-operative MRI

Intervention type: PROCEDURE
Intervention: Liver resection
Description: Hepatectomy with an intention to cure

Intervention type: OTHER
Intervention: Histopathology diagnosis of resected liver specimen
Description: Histopathology diagnosis by expert pathologist.
Study: NCT02499510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GoldenFlow Stent
Description: The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
Study: NCT00936676

Intervention type: DRUG
Intervention: rasagiline mesylate
Description: During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
Study: NCT04538287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AtaCor StealthTrac Lead
Description: Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AtaCor StealthTrac Lead
Description: Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AtaCor StealthTrac Lead
Description: Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AtaCor StealthTrac Lead
Description: Subjects are assigned non-randomly to receive one of the four AtaCor StealthTrac leads being evaluated in the study.